Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term access programme for mepolizumab in severe asthma
NL-OMON43801Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in severe asthma, sponsored by GSK. Started Sep 2015; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on NL-OMON43801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43801.